About ranibizuma b
Vascular endothelial growth factor inhibitor
Used for
- Treats wet age-related macular degeneration
- Treats diabetic macular edema and diabetic retinopathy
- Treats macular edema after retinal vein blockage
- Treats certain forms of myopic choroidal neovascularization
Usual adult dose
Usually 0.5 mg injected into the eye monthly at first; dosing intervals may later be extended.
Usual dose in children
Not routinely used in children; dosing depends on the specific retinal condition and specialist guidance.
Common side effects
- Eye inflammation, pain, floaters, or increased eye pressure
- Conjunctival bleeding or eye irritation
- Cataract or retinal detachment
- Rarely, stroke or other blood clots
Important warnings
- Given only by an eye specialist as an injection into the eye
- Eye infection or inflammation can occur; urgent assessment is needed for severe pain or vision changes
- May increase eye pressure soon after injection
- Use caution with recent stroke or heart attack
Pregnancy
Limited human information; potential fetal risk is uncertain. Avoid during pregnancy unless treatment is necessary.
Breastfeeding
It is unknown whether ranibizumab enters breast milk; discuss treatment and nursing with a clinician.
Interactions
- No important systemic drug interactions are established; tell the eye specialist about all medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.